Evaluation of the Accelerate Pheno System for Identification of Clinical Isolates and Minocycline Susceptibility Testing.

The Accelerate Pheno system (AXDX) is a rapid phenotypic bacterial identification and susceptibility testing system which is approved for use with positive blood cultures. is a nosocomial pathogen for which the limited treatment options include minocycline in the case of multidrug resistance. Here, we studied the performance of identification and minocycline susceptibility testing by AXDX using 101 contemporary sp. clinical isolates. Overall, the sensitivity for and complex identification was 100% (73/73) and 97.6% (82/84), respectively. Specificity for complex identification was 86.6% (13/15). The essential agreement of minocycline susceptibility results (±1 log MIC agreement) of AXDX MICs with reference broth microdilution was 98.0% (96/98). There were no very major errors or major errors. Overall, 24.5% (24/98) of results yielded minor errors. AXDX reliably identified and predicted minocycline susceptibility results, which should help guide treatment choices in a timely manner for infections where options are limited.